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Felipe Fernández-Cuenca1, Virginia Palomo1, Miguel Angel Muniain1,2 and Jesús Rodríguez-Baño1,2Abstract
Background: To describe the long term outcome of patients who interrupted highly active antiretroviral therapy
(HAART) once, identify the variables associated with earlier need to re-start HAART, and the response when therapy
was resumed. A retrospective observational cohort of 66 adult patients with HIV-1 infection who interrupted HAART
with a CD4+cell count ≥350 cells/μL and undetectable viral load (VL) was performed. The pre-established CD4+ cell
count for restarting therapy was 300cells/μL. Cox regression was used to analyse the variables associated with
earlier HAART reinitiation.
Results: The median follow-up was 209 weeks (range, 64–395). Rates of HIV-related or possible HIV-related events
were 0.37 (one case of acute retroviral syndrome) and 1.49 per 100 patient-years, respectively. Two patients died
after re-starting therapy and having reached undetectable VL. Three patients suffered a sexually transmitted disease
while off therapy. Fifty patients (76%) resumed therapy after a median of 97 weeks (range, 17–267). Age, a nadir of
CD4+ <250 cells/μL, and a mean VL during interruption of >10,000 copies/ml were independent predictors for
earlier re-start. The intention-to-treat success rate of the first HAART resumed regimen was 85.4%. There were no
differences by regimen used, nor between regimens that were the same as or different from the one that had
been interrupted.
Conclusions: Our data suggest highly active antiretroviral therapy may be interrupted in selected patients because
in these patients, when the HAART is restarted, the viral and clinical response may be achieved.
Keywords: HIV-1, Antiretroviral therapy, Treatment interruption, Outcome, Cohort studyBackground
High active antiretroviral therapy (HAART) has com-
pletely changed the prognosis of HIV infection [1]. Al-
though nowadays HAART is recommended as a life-long
therapy [2-4], interruptions of therapy in patients with
undetectable HIV viral load (VL) while on therapy
have been evaluated, both as fixed periods with and
without therapy (structured interruptions) and as a strat-
egy in which therapy is re-started after interruption
when the CD4+ lymphocyte count diminish below a pre-
determined level (CD4+ guided interruptions). A meta-* Correspondence: carmenmachadoec@yahoo.es
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reproduction in any medium, provided the oranalysis concluded that structured interruptions had not
demonstrated short-term safety; and long term data were
lacking for CD4+ guided interruptions [5]. Results from
a later meta-analysis suggested that interruption strat-
egies are associated with a low risk of death or aids-
defining events, although the risk is not significant if the
threshold for restarting HAART is established at a rela-
tively high level of CD4+ cell count [6].
Beyond pre-established strategies, interruption of
HAART are more frequent that desired due to different
reasons [7], such as patient’s decision to stop therapy, re-
luctance to alternatives in the event of intolerance to the
current regimen, etc. When an interruption occurs,
questions about the short and long term risk of compli-
cations, and the probability of reaching virologic andal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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quently arouse.
The objectives of this study were to describe the very
long term outcome of patients who interrupted HAART
for ≥3 months while being in good immunologic condi-
tion and with undetectable VL, to evaluate the variables
associated with an earlier need to re-start therapy, and
to analyse the virologic and immune response to the re-
introduction of HAART.
Patients and methods
Study design
A retrospective cohort analysis was performed. Patients
were considered eligible if included in Hospital Universi-
tario Virgen Macarena cohort of adult patients (age >18
years) patients with chronic HIV-1 infection, and had
interrupted the antiretroviral drugs for at least 12 weeks
between January 2001 and December 2004. Only
patients who interrupted a stable HAART regimen while
clinically stable, with undetectable VL (<50 copies/mL)
and stable CD4+ cell count ≥350/μl for the last 6
months were included.
Patients were visited at least every 12 weeks. In all
routine visits, a clinical examination and routine blood
tests including a CD4+ cell count and RNA HIV-1 viral
load testing (Amplicor HIV-1 Monitor Test version 1.5,
Roche Diagnostic System) were performed. Decisions
about restarting HAART were discussed in every visit
with the patients; the following criteria were pre-
established as indications to reinitiate therapy: CD4+ cell
count < 300 cells/μL (the attending physicians had previ-
ously agreed to consider this CD4+ count threshold for
resuming therapy), pregnancy, acute retroviral syn-
drome, thrombocytopenia, and any other B or C event
[8]. Data were collected from the structured charts until
death or lost to follow-up, and patients were censored in
October 2008 to perform this analysis.
The study was approved by the Ethic Committee from
Hospital Universitario Virgen Macarena. The need to
obtain written consent informs was waived because of
the retrospective nature of the study.
Variables and definitions
From all patients, the following variables were collected:
age, gender, ethnics, risk behaviours, number of years
since the diagnosis of HIV infection, toxic habits, HCV
and HBV coinfection, HIV category before interruption,
CD4+ cell nadir and in the interruption, number and
duration of HAART regimens, previous virologic fail-
ures, and previous available resistance-related mutations.
The main endpoints of the study were the occurrence
of HIV-related or possibly related events and death from
any cause. The following events were considered HIV-
related: acute retroviral syndrome, all B events accordingto 1993 CDC classification [8], and all aids-defining
events from the 2008 CDC classification [9]. The follow-
ing were considered as possibly HIV-related: bacterial
pneumonia, any type of malignancy, thrombocytopenia,
and death from any cause except if clearly unrelated
to HIV, its complications or its influence on other
conditions. All other events were considered as non
HIV-related.
Secondary end-points were: time until HAART was
restarted and response to HAART after interruption.
The latter was defined as failure in an intention to treat
analysis if any of the following circumstances occurred:
undetectable VL (<50 copies/ml) had not been reached
in the visit when the HAART regimen was changed or
at the end of follow-up [10], the HAART regimen had to
be changed because of intolerance, death from any
cause, or HIV-related events [8,9]. Otherwise it was con-
sidered successful. Virologic failure was also analysed
per protocol in patients who did not change the HAART
regimen because of intolerance. Adherence to therapy
was measured by the SMAQ3 questionnaire [11].
Statistical analysis
Time until reinitiation of HAART was studied using
Kaplan-Meier curves. The crude association between ex-
posure to the different variables and the time until re-
start of therapy was studied by the log-rank test.
Multivariate analysis was peformed by Cox regression.
Analysis were performed with SPSS 15.0.
Results
We included 66 patients. Their features are summarised
in Table 1. The reasons for treatment interruption
included: proposal of the attending physician, patient´s
ance and poor adherence (Table 1). The median follow-
up from HAART interruption was 209 weeks (range,
64–395), with a total of 287 patients-year. Over the
study period, 3 patients (4.54%; 1.04 events per 100
patients-year) developed HIV-related events (an acute
retroviral syndrome and two thrombocytopenias during
HAART interruption); no patient developed any C
event. Three patients (4,54%; 1.39 events per 100
patients-year) developed 4 events possibly related to
HIV (Table 2); 2 of them occurred during HAART inter-
ruption (2 bacterial pneumonia) and other 2 after
HAART was restarted, in both cases when undetectable
VL has been reached (decompensation of liver cirrhosis
due to HCV 23 weeks after restart; and Hodgkin disease,
100 weeks after restart; both patients died as a conse-
quence of the events; both patients had stopped HAART
on their own). Other non HIV-related events (all hap-
pened during interruption) were: 2 acute hepatitis due to
VHA (probably sexually transmitted), one urethritis due
to Neisseria gonorrhoeae, one pyelonephritis due to
Table 1 Features of included patients. VL: viral load.
HAART: highly active antiretroviral therapy
Variable Number of patients (percentage),
except where specified
Median age (range) 37 years (23–63)
Male gender 45 (68)
Risk category
Injection drug users 28(42)
Men who have sex with men 16 (24)
Heterosexual 22 (34)
Toxic habits
Current smoking 46 (69)
Alcholism 22 (33)
Methadone Maintenance
Treatment
20 (30)
Median time since diagnosis
of HIV infection (range)
10 years (2–16)
CDC category
A 54 (82)
B 6 (9)
C 6 (9)
Number of previous antiretroviral regimens
1 13 (20)
2 16 (24)
3 or more 37 (56)
Median time on HAART before
interruption (range)
284 weeks (60–512)
Adherence <80% to any previous
antiretroviral therapy
20 (30)
Previous virologic failure with any antiretroviral regimen
No 53 (81)
Yes 13 (19)
HCV coinfection 33 (50)
HBV coinfection 2 (3)
Median HIV-1 VL at diagnosis
(range)
23.750 copies/mL (100–1.511.000)
Median nadir CD4+ cell count
(range)
252 cells/μL (50–552)
Main reason for the interruption of HAART
Proposed by physician 33 (50)
Intolerance to current regimen 20 (30,3)
Decision of the patient 10 (15,2)
Problems for an appropriate
adherence
3 (4,5)
Median CD4+ cell count at
interruption (range)
745 (350–2132)
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no other cardiovascular events. If all potentially HIV-
related events were counted including those occurring
after HAART was resumed, the rate of events would be
1.64 events per 100 patients-year (follow up included the
time after therapy resume).At the end of the study period, 50 patients (76%) had
restarted HAART. The median duration of interruption
was 97 weeks (range, 17–267). The probability of
remaining without HAART is shown in Figure 1. The
evolution of CD4+ cell count and VL during the inter-
ruption is shown in Figure 2. A nadir CD4+ cell count
<250 per μl (p<0.001), and category B or C (p=0.003)
were associated with shorter period of interruption in
the crude analysis; these variables were included in the
multivariate analysis together with age, and mean VL
during interruption >10.000 copies/ml (since the p value
for the latter was <0.1). By a backward process, the
variables selected as predictors of shorter time of inter-
ruption were: higher age (HR per year = 1.07; 95% CI:
1.02-1.12; p=0.002), a nadir CD4+ cell count <250 per μl
(HR = 3.70; 95% CI: 1.92-7.14; p <0.001) and mean VL
during interruption >10.000 copies/ml (HR = 3.51; 95%
CI: 1.56-7.14; p=0.002). The remaining variables were
not associated with shorter period of interruption in the
crude analysis either with the time from resuming ther-
apy to reach undetectable load.
In the analysis of response to restarted HAART, we
excluded 2 patients whose follow up at the end of
study period was <12 weeks; thus, 48 patients
were evaluated. Among them, the median follow-up
after HAART restarted was 101 weeks (range, 12–
254). The median CD4+ cell count when HAART was
restarted was 266 (range, 40–999), and the median VL
was 51.400 copies/ml (range, 50->100.000). The prob-
ability of remaining with detectable HIV-1 viral load
(>50 copies/ml) after reinitiating antiretroviral therapy
is shown in Figure 3.
The main reason for restarting HAART was the de-
crease in the CD4+ cell count in 43 patients (88%),
HIV-related or possibly related events in 3 (6%), patient’s
request in 2 (4%), and pregnancy in 1 (2%). As explained
above, there were no B o C events after HAART was
restarted, and 2 patients died (Table 2).
All patients received 2 nucleoside or nucleotide
reverse transcriptase inhibitors (NRTI) plus another
drug: a non-nucleoside reverse transcriptase inhibitor
(NNRTI), 25 patients; a boosted protease inhibitor (PI),
17 patients; or another drug, 4 patients. In an ITT ana-
lysis, the success rate were 84%, 88.2% and 100%; the
differences between groups were not statistically signifi-
cant (p value for NNRTI vs PI, 0.7).
The initial regimen was based on the same groups of
drugs than the one that was interrupted in 25 patients
(52%). Among them, 16 received an initial regimen
based on NNRTI; 14 reached undetectable VL, one
was changed to PI because of intolerance, and the other
was changed to PI because of virologic failure (a geno-
typic study could not be performed because the VL was
always <500 copies/ml). Eight received an initial regimen
Table 2 Events detected during the follow up of 66 patients who interrupted antiretroviral therapy
Patient Event Weeks after
interruption
Situation when event
occurred
CD4+ cell count in
the interruption
CD4+ cell count when
the event occurred
Outcome
1 Bacterial pneumonia 48 Interrupted 480 234 Cured
Hodgkin’s lymphoma 164 100 weeks after HAART was
restarted (VL<50 since week 4)
480 415 Dead
2 Decompensation of
HCV-related liver
cirrhosis
97 23 weeks after HAART was
restarted (VL<50 since week 4)
415 120 Dead
3 Thrombocytopenia 196 Interrupted 366 234 Resolved after
HAART restarted
Bacterial pneumonia 200 Interrupted 366 234 Cured
4 Thrombocytopenia 161 Interrupted 1089 580 Resolved after
HAART restarted
5 Acute retroviral syndrome 12 Interrupted 576 415 Resolved after
HAART restarted
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other was changed because of intolerance. The other
patient was treated with 3 NRTI and reached undetect-
able VL.
The initial regimen was based on a different group of
drugs than the one that was interrupted in 23 patients.
Among them, the initial regimen after interruption was
based in a NNRTI in 9 patients; 7 of them reached un-
detectable VL, one was changed because of intolerance,
and the other needed to be changed to a PI-based regi-
men because of virologic failure; genotypic test could
not be performed. Nine received an initial regimen based
on PI; 8 reached undetectable VL, and one failed; muta-
tions found were 62V, 75I, 118I, and 184I (reverse120967248240
1,0
0,8
0,6
0,4
0,2
0,0
P
ro
ba
bi
lit
y 
of
 r
em
ai
ni
ng
 w
ith
ou
t 
an
tir
et
ro
vi
ra
l t
he
ra
py
Weeks s
Figure 1 Probability of remaining off antiretroviral therapy after intertranscriptase gene) and 77I (protease gene). This patient
had a low adherence and was still in virologic failure at
the end of follow-up. The 4 patients with regimens base
on other drugs reached undetectable VL.
In an ITT analysis, we found no difference between
patients who restarted HAART with a regimen based on
the same families of drugs that had been interrupted and
those who restarted with a different regimen (success
rate, 88% vs 91%, p=0.7).
The evolution of CD4+ cells is shown in Figure 4. In
patients with 96 week follow up after resuming the ther-
apy, the median CD4+ cell count was 727 cells/ml when
HAART was interrupted, and 529 cells/ml at 96 week
after HAART was restarted (p=0,001).288264240216192168144
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Figure 2 Evolution of CD4+ cell count (2A) and HIV-1 viral load (2B) after HAART interruption. Data are expressed as median values
(horizontal lines), interquartile range (grey boxes), and percentile 95 (vertical lines). The number of patients with data in each time period is
provided over each vertical line.
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Our study show that long term prognosis of patients
who interrupted HAART once for more than 12 weeks,
while being in a stable situation, and with the intention
to restart HAART once CD4+ cells were ≤300 per μL
was good, although some considerations need to be
done.
The hypothesis for investigating HAART interruptions
as a strategy included: the potential effect of viral re-
bound in stimulating the immunologic response against
HIV, and the potential reduction in HAART-related ad-
verse events, in the fatigue of patients, and in the costs
of therapy. Structured treatment interruptions, with
fixed cycles on and off therapy, have not demonstrated a
comparable short-term safety in comparison with con-
tinuous treatment [5]. On the other side, CD4+−guidedinterruptions have been investigated both in randomised
clinical trials and cohort studies. A recently published
meta-analysis considered 7 randomised clinical trials (al-
though only the 4 of them with >100 patients-year of
follow-up were actually included), and 11 cohort studie
[6]. Even though the heterogeneity of the studies and the
possibility of a publication bias limit the conclusions of
the meta-analysis, the results suggest that the risk of
events (including aids-defining events and deaths) were
higher in patients with interruptions; however, the effect
was small (one death per 100 patients-year). In the co-
hort studies, the rate of events ranged between 0 (8
studies) and 3.2 per 100 patients-year, and was higher
when HAART was restarted with <250 CD4+cells per
μl. Thus, structured interruptions of HAART are not
recommended out of well-controlled research studies
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Figure 3 Probability of remaining with detectable HIV-1 viral load (>50 copies/mL) after reinitiating antiretroviral therapy.
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guided treatment interruptions may be safe [12]. To our
knowledge, our study includes the more prolonged fol-
low-up, and we could not detect any aids-defining event;
the rate of HIV-related events is intermediate among the
published cohorts. However, it should be noted that our
patients only interrupted HAART once.
Two patients in our cohort died. Both had interrupted
HAART on their own, and both reached undetectable
VL after restarting therapy. However, one developed a
Hodgkin’s lymphoma, and the other had a decompensa-
tion of HCV-related liver cirrhosis. Since non-aids-
defining malignancies and progression of HCV-related
liver fibrosis are conditions in which HAART may have
a preventive role (though the issue is controversial), this
should be considered in the case of an interruption.
Also, the fact that the CD4+ cell count level at the inter-
ruption was not reached again after therapy was
resumed, is another aspect to be considered.
The interruptions analysed in our study occurred in a
specific context in the history of HAART: the previous
hypothesis that HIV infection could be cured was
proved false; the late side effects of some drugs were
emerging; and the alternative regimens were scarce. Ob-
viously, the context today is different. However, based
on the long term follow-up of our series, and since still
most present regimens are based on 2 NRTI plus a
NNRTI or PI, we think our data may be useful in the
decision-making process and advice to patients when an
interruption of HAART has happened or is being dis-
cussed. The variables associated to a shorter time for
restarting HAART (higher age, CD4+ nadir <250 cells/
μL, and a higher VL during the interruption) are sound
and in agreement with previous investigations [13-16],and may be used to identify patients who would need a
more close follow-up.
A key question in patients who interrupt HAART is
the possibility of HIV transmission [17]. In our series,
and even though this aspect had been specifically dis-
cussed with all of them, 3 of our patients suffered a
sexually transmitted disease, indicating that they may
have also transmitted HIV during the same risk practise.
There is no doubt that this is a very important issue to
consider and discuss in the cases of interruptions.
One potential worry after an interruption is whether
the probability of reaching again virologic control is
compromised. The vast majority of our patients suc-
ceeded in controlling VIH replication, although un-
detectable VL was reached somehow late in many
patients. Even though the number of patients is low, we
did not find differences between NNRTI- and PI-based
regimens, or if the regimen was similar to the one that
was interrupted or not. Interruptions of NNRTI-based
regimens has been associated to selection of mutations
conferring resistant to these drugs in previous studies,
although this may be more frequent in the case of mul-
tiple interruption [18,19] In our study, only one patient
among the 16 who interrupted and restarted a NNRTI-
based regimen showed a virologic failure (mutations
cannot be studied).
Our study has several limitations that should be con-
sidered. First, it was performed in only one center. Sec-
ond, metabolic parameters, inflammation markers or
cardiovascular risks were not assessed, therefore poten-
tial implications of the HAART interruption related to
these items could not be analysed. And third, we could
not compare the data with a control group of matched
patients who continued therapy.
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Figure 4 Evolution of CD4+ cell count during HAART interruption (4A) and after HAART restart (4B) in patients who resumed
antiretroviral therapy. Data are expressed as median values (horizontal lines), interquartile range (grey boxes), and percentile 95 (vertical lines).
The number of patients with data in each time period is provided over each vertical line.
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Our data suggest that restarting HAART when a single
interruption occurs is not an emergency and that it is
safe in most patients to wait while reinforcing the im-
portant of a correct adherence and the alternatives to
potential adverse effects of HAART. The risk of non-
aids-defining events, worse evolution of coinfections,
and transmission of the HIV should be specifically
discussed.
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